Contralateral nodal failures in oropharyngeal cancers after TORS and unilateral neck management: a retrospective study by Axel Sahovaler, John J. W. Lee, Wei Xu, Susie Su, Ali Hosni, Andrew Bayley, David P. Goldstein, John R. de Almeida

“…Conclusion In selected patients with lateralized oropharyngeal cancer, treatment with TORS and ipsilateral management of the neck may be oncologically safe without significant risk of contralateral failure. …”
Get full text

Multidisciplinary Collaboration and Novel Technological Advances in Hadron Therapy by Manjit Dosanjh PhD, Alberto Degiovanni PhD, Maria Monica Necchi PhD, Elena Benedetto PhD

“…Hadron Therapy (HT), which employs accelerated beams of protons, carbon ions, and other charged particles, represents a significant frontier in cancer treatment. This modality offers superior precision and efficacy compared to conventional methods, delivering therapeutic the dose directly to tumours while sparing healthy tissue. …”
Get full text

Fluorescence imaging‐guided lipid droplets‐localized photodynamic therapy by Shan Wang, Qiang Wang, Yang Lv, Zhe Liu, Kippeum Lee, Dongeun Kim, Miae Won, Jianliang Shen, Jong Seung Kim

“…Abstract Photodynamic therapy (PDT) has emerged as a promising strategy for cancer treatment due to its non‐invasive nature and high specificity toward malignant tissues. …”
Get full text

Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape by Joy A Awosika, Cecilia Monge, Tim F Greten

“…Precision medicine has emerged as a cornerstone in cancer treatment revolutionizing our approach across malignancies. …”
Get full text

Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics by Peter S. Kim, Joseph J. Crivelli, Il-Kyu Choi, Chae-Ok Yun, Joanna R. Wares

“…The past century's description of oncolytic virotherapy as a cancer treatment involving specially-engineered viruses that exploit immune deficiencies to selectively lyse cancer cells is no longer adequate. …”
Get full text

Ellagic acid: A potent glyoxalase-I inhibitor with a unique scaffold by Al-Shar’i Nizar A., Al-Balas Qosay A., Hassan Mohammad A., El-Elimat Tamam M., Aljabal Ghazi A., Almaaytah Ammar M.

“…The glyoxalase system, particularly glyoxalase-I (GLO-I), has been approved as a potential target for cancer treatment. In this study, a set of structurally diverse polyphenolic natural compounds were investigated as potential GLO-I inhibitors. …”
Get full text

Natural killer cell engagers for cancer immunotherapy by Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi, Arash Hatefi

“…Ultimately, this article presents an overview of the current landscape and future prospects of NKCE-based cancer immunotherapy, emphasizing its potential to revolutionize cancer treatment.…”
Get full text

Evaluating Medicinal Plants for Anticancer Activity by Elisha Solowey, Michal Lichtenstein, Sarah Sallon, Helena Paavilainen, Elaine Solowey, Haya Lorberboum-Galski

“…Most chemotherapeutic drugs for cancer treatment are molecules identified and isolated from plants or their synthetic derivatives. …”
Get full text

Docking to Explicate Interface between Plant-Originated Inhibitors and E6 Oncogenic Protein of Highly Threatening Human Papillomavirus 18 by Satish Kumar, Lingaraja Jena, Maheswata Sahoo, Mrunmayi Kakde, Sangeeta Daf, Ashok K. Varma

“…Traditionally, different natural compounds such as withaferin A, artemisinin, ursolic acid, ferulic acid, (-)-epigallocatechin-3-gallate, berberin, resveratrol, jaceosidin, curcumin, gingerol, indol-3-carbinol, and silymarin have been used as hopeful source of cancer treatment. These natural inhibitors have been shown to block HPV infection by different researchers. …”
Get full text

Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer by Ruohong Lin, Jiaxing Cheng, Jinlong Zhao, Liang Zhou, Jian Li, Xinchun Yang

“…Recently years, drug combination therapy has become a promising strategy for cancer treatment. Objective To evaluate the therapeutic efficacy of the combination of the anti-angiogenic drug PEP06 (TB01) and the cytotoxic drug Trifluridine/Tipiracil (TAS-102) in human CRC HCT-116 xenograft mouse model. …”
Get full text

Current status and future prospects of molecular imaging in targeting the tumor immune microenvironment by Xiang Wang, Xiang Wang, Weifen Shen, Weifen Shen, Lingjun Yao, Lingjun Yao, Chao Li, Chao Li, Huiming You, Huiming You, Duancheng Guo, Duancheng Guo

“…The future outlook emphasizes the potential of molecular imaging to enhance personalized cancer treatment through the integration of artificial intelligence and the development of novel imaging probes. …”
Get full text

Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review by M. Bilski, D. Surdyka, I. Paśnik, M. Bilska, P. Cisek, P. Korona, J. Szumiło, L. Grzybowska-Szatkowska

“…The case shows that adjuvant radiotherapy as part of cancer treatment strategy may prolong the overall survival.…”
Get full text

Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer by Junko Tsuchida, Masayuki Nagahashi, Kazuaki Takabe, Toshifumi Wakai

“…We suggest that S1P is one of the key molecules to overcome the resistance to the drug therapies, such as hormonal therapy, anti-HER2 therapy, or chemotherapy, all of which are crucial aspects of a breast cancer treatment.…”
Get full text

Identification of Proteins and Genes Associated with Hedgehog Signaling Pathway Involved in Neoplasm Formation Using Text-Mining Approach by Nadezhda Yu. Biziukova, Sergey M. Ivanov, Olga A. Tarasova

“…Analysis of molecular mechanisms that lead to the development of various types of tumors is essential for biology and medicine, because it may help to find new therapeutic opportunities for cancer treatment and cure including personalized treatment approaches. …”
Get full text

Canine Mammary Tumors as a Potential Model for Human Breast Cancer in Comparative Oncology by Amirhossein Razavirad, Sanaz Rismanchi, Pejman Mortazavi, Ahad Muhammadnejad

“…In total, 64 canine mammary tumors were selected to study the most common markers, which are applicable for human breast cancer treatment, including estrogen and progesterone receptors (ER and PR), human epidermal growth factor (HER2/neu), Ki67, and cyclooxygenase 2 (Cox2). …”
Get full text

Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context by Yuichi Adachi, Kotaro Miyake, Kika Ohira, Shingo Satoh, Kentaro Masuhiro, Ryuya Edahiro, Yuya Shirai, Maiko Naito, Yujiro Naito, Takayuki Shiroyama, Shohei Koyama, Haruhiko Hirata, Kota Iwahori, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh

“…Summary: Background: Photoimmunotherapy (PIT) is a potent modality for cancer treatment. The conventional PIT regimen involves the systemic delivery of an antibody–photoabsorber conjugate, followed by a 24-h waiting period to ensure adequate localisation on the target cells. …”
Get full text

Lidocaine could promote the cuproptosis through up-regulating the long noncoding RNA DNMBP-AS1 in Hep-2 cells by Wei Liu, Yi Yu, Yi He, Meihong Lv

“…The results of this study offered initial optimism that lidocaine could be used in an adjuvant or neoadjuvant fashion in cancer treatment.…”
Get full text

Organ preservation, for rectal cancer: general overview of the latest data from phase III randomized trials by Syrine Ben Dhia, Damien Chauviere, Diana Mitrea, Renaud Schiappa, Tanguy Pace Loscos, Emmanuel Chamorey, David Baron

“…Despite the lack of international consensus on the optimal OP protocol, past and ongoing randomized trials provide valuable findings into the evolving management strategies of rectal cancer treatment. The presented data supports the role of randomized phase III trials to provide evidence for a change in clinical practice. …”
Get full text

Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition by Aimin Yang, Xia Xiao, Mingfeng Zhao, Amanda C. LaRue, Bradley A. Schulte, Gavin Y. Wang

“…Therefore, targeting of the mTOR pathway is an attractive strategy for cancer treatment and several mTOR inhibitors, including AZD8055 (AZD), a novel dual mTORC1/2 inhibitor, are currently in clinical trials. …”
Get full text

Targeting fucosyltransferase FUT8 as a prospective therapeutic approach for DLBCL by Hao Xu, Qi Li, Yuchen Zhang, Chuan He, Xinyun Zhang, Zhiming Wang, Meifang Zhao, Yali Chai, Wenzhuo Zhuang, Bingzong Li

“…The emergence of natural products and their derivatives has notably influenced cancer treatment, making morusinol, a medicine-derived monomer, a promising candidate. …”
Get full text